Study: Prices for existing drugs surge after FDA approval, costing billions

Feb 26, 2020 - 02:44 PM
drugs

Four drugs used in hospitals for years increased their prices between 525% and 1,644% after receiving formal approval through the Food and Drug Administration’s Unapproved Drug Initiative, according to an analysis released today by Vizient. 

Launched in 2006, the initiative requires drugs marketed before FDA began regulating drug safety and efficacy in 1938 to receive FDA approval to stay on the market. 

“Depending on the approval, manufacturers receive periods of exclusivity ranging from three to seven years,” said Dan Kistner, group senior vice president for pharmacy solutions at Vizient. “If a patent is awarded, the manufacturer could have market exclusivity for 20 years.” 

The study looks at four drugs approved through the UDI process since 2013, and estimates they will increase U.S. health care spending by $20.25 billion during their market exclusivity periods. With 19 additional drugs poised to go through this approval process, “the combined impact of the higher costs for these 23 drugs could be $29 billion,” Kistner said.
 

Related News Articles

Headline
AHA requests CMS reconsider provisions within Medicaid community engagement rule
The AHA July 31 provided comments to the Centers for Medicare & Medicaid Services on its interim final rule on Medicaid community engagement requirements.…
Headline
DOL proposal seeks to modernize delivery of disclosures for group health plans 
The Department of Labor July 22 released a proposed rule to modernize how group health plans deliver required disclosures. The proposal would create a safe…
Headline
CMS issues proposed provider tax rule
The Centers for Medicare & Medicaid Services today released a proposed rule that would update Medicaid provider tax policies included in the July 2025…
Headline
AHA comments to CMS on proposed rule covering Medicaid supplemental payments
The AHA provided comments July 21 to the Centers for Medicare & Medicaid Services on its proposed rule to modify policies governing Medicaid…
Headline
District court pauses 8 provisions from 2027 notice of benefit and payment parameters final rule
The U.S. District Court for the District of Maryland July 16 enjoined eight provisions from the Centers for Medicare & Medicaid Services’ 2027 notice of…
Headline
Draft guidance released for 2028 cycle of Medicare drug price negotiations 
The Centers for Medicare & Medicaid Services July 16 released draft guidance for the 2028 cycle of negotiations under the Medicare Drug Price Negotiation…